<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123161</url>
  </required_header>
  <id_info>
    <org_study_id>ICTuS2/3</org_study_id>
    <secondary_id>P50NS044148</secondary_id>
    <secondary_id>P50NS044227</secondary_id>
    <nct_id>NCT01123161</nct_id>
  </id_info>
  <brief_title>The Intravascular Cooling in the Treatment of Stroke 2/3 Trial</brief_title>
  <acronym>ICTuS2/3</acronym>
  <official_title>Phase 2/3 Study of Intravenous Thrombolysis and Hypothermia for Acute Treatment of Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether the combination of thrombolysis and
      hypothermia is superior to thrombolysis alone for the treatment of acute ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A stroke is usually caused by a blockage in one of the arteries that carries blood to the
      brain. Research has shown that tissue plasminogen activator (tPA)—a naturally occurring
      protein that opens blocked arteries by dissolving blood clots — activates the body's ability
      to dissolve recently formed blood clots and reduces or prevents the brain damage caused by a
      stroke.

      The Food and Drug Administration (FDA) has approved the use of tPA for people having a stroke
      when taken within 3 hours of stroke onset.

      Researchers believe that a lower body temperature (hypothermia) may be beneficial while a
      stroke is happening because hypothermia may prevent further brain injury, or may make the
      stroke less damaging.

      Patients will receive a standard stroke evaluation, which includes blood tests, a computed
      tomography (CT) scan, complete physical and neurological examinations, and an
      electrocardiogram (EKG) to determine eligibility for the study.

      There are two study groups - tPA alone or tPA with cooling (hypothermia). Participants will
      be randomly assigned to one of the two study groups. Length of participation (including
      observation after the patient leaves the hospital) is 90 days.

      This study is part of the Specialized Program of Translational Research in Acute Stroke
      (SPOTRIAS), which allows researchers to enhance and initiate translational research that
      ultimately will benefit stroke patients by treating more patients in less than 2 hours, and
      finding ways to treat additional patients later.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The ICTuS 2 portion of the trial has been halted and data will be analyzed.
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Randomized to normothermia or hypothermia</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome is the Proportion of Patients Achieving a Favorable Outcome Defined as Modified Rankin Scale Score of 0 or 1, Assessed 90 Days After Treatment.</measure>
    <time_frame>90 days</time_frame>
    <description>Modified Rankin describes disability: 0 is free of any disability or symptoms, 6 is death, and higher grades between 0 and 6 reflect progressively greater disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Any Intracranial Hemorrhage (ICH) Within 48 Hours of Stroke Onset</measure>
    <time_frame>48 hours</time_frame>
    <description>Incidence (number) of any intracranial hemorrhage (ICH) (whether or not symptomatic) within 48 hours of stroke onset will be presented by treatment group and overall.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Any Symptomatic Intracranial Hemorrhage (sICH) Within 48 Hours of Stroke Onset</measure>
    <time_frame>48 hours</time_frame>
    <description>Incidence (number) of Symptomatic ICH (sICH) within 48 hours of stroke onset will be presented by treatment group and overall. Patients with neuroworsening (4 or more point increase in NIHSS , or a decline in the NIHSS consciousness item 1A score of more than 1 point, or a motor deterioration lasting more than 8 hours, all not due to iatrogenic cause) and hemorrhage seen on brain images in whom the investigator attributes the clinical change to the hemorrhage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Pneumonia</measure>
    <time_frame>7 days or discharge whichever comes first</time_frame>
    <description>Number subjects diagnosed with pneumonia according to CDC criteria will be presented by treatment group and overall, regardless of seriousness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>90 Day Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Mortality prior to the 90-day evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Barthel Index Measure of Activities of Daily Living;</measure>
    <time_frame>90 days</time_frame>
    <description>The Barthel index measures independence in activities of daily living from 0 (worst) to 100 (best) in 5 point increments. Higher scores between 0 and 100 reflect progressively greater levels of independence. Scores were dichotomized at 90 so that a score of 95 or 100 was considered a successful treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS Scores at 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The National Institutes of Health Stroke Scale (NIHSS) is used to quantify neurological deficit. The scale ranges from 0 (best) to 42 points (worst). Between scores of 0 to 42, higher values reflect progressively greater deficit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>Group1: IV t-PA and normothermia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV tpa and normothermia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : IV t-PA and hypothermia and anti-shivering treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV tpa and hypothermia and anti-shivering treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hypothermia and anti-shivering treatment</intervention_name>
    <description>Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming</description>
    <arm_group_label>Group 2 : IV t-PA and hypothermia and anti-shivering treatment</arm_group_label>
    <other_name>cooling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group1: IV t-PA and normothermia</intervention_name>
    <description>Group 1 will t-PA as standard of care and normothermia</description>
    <arm_group_label>Group1: IV t-PA and normothermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 22 to 82 years old inclusive

          2. Patient receiving IV rt-PA using standard guidelines

          3. NIHSS score ≥ 7 and ≤ 20 (right hemisphere) or ≥ 7 and ≤ 24 (left hemisphere) at the
             time of randomization

          4. Pre-stroke mRS 0-1

          5. Able to begin endovascular phase of hypothermia within 2 hours of tPA completion

          6. Written Informed Consent, signed and dated by the patient (or patient's authorized
             representative)

        Exclusion Criteria:

          1. Etiology other than ischemic stroke

          2. Item 1a on NIHSS &gt; 1 at the time of randomization

          3. Clinical symptoms consistent with brainstem or cerebellar stroke

          4. Classic lacunar syndrome with imaging confirmation of small deep ischemia, but
             randomization will not be delayed for neuroimaging other than initial scan to exclude
             hemorrhage

          5. Known contraindications to hypothermia, such as known hematologic dyscrasias that
             affect thrombosis (cryoglobulinemia, Sickle cell disease, serum cold agglutinins), or
             vasospastic disorders such as Raynaud's or thromboangiitis obliterans

          6. Known co-morbid conditions that are likely to complicate therapy in the opinion of the
             investigator, e.g., i. Heart failure (NYHA class III and IV)* ii. Uncompensated
             arrhythmia iii. Severe Liver disease iv. History of pelvic or abdominal mass likely to
             compress inferior vena cava v. IVC filters vi. HIV positive vii. Clinically active
             hypo or hyperthyroidism viii. Renal insufficiency likely to impair meperidine
             clearance ix. Chronic ethanol abuse x. History of HIT (heparin induced
             thrombocytopenia)

          7. Pregnancy (All women of child-bearing potential must have a negative pregnancy test,
             urine or blood, prior to therapy.)

          8. Medical conditions likely to interfere with patient assessment.

          9. Known allergy to meperidine or buspirone

         10. Currently taking or used within previous 14 days MAO-I class of medication.

         11. Life expectancy &lt; 6 months

         12. Not likely to be available for long-term follow-up

         13. Use, or planned use, of intra-arterial thrombolysis, mechanical clot removal, or other
             experimental or approved acute therapy for this stroke event

         14. Chest radiograph or clinical presentation suggestive of pneumonia or clinically
             significant pulmonary edema at baseline.

         15. Temperature upon admission greater than or equal to 38°C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick D. Lyden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas M. Hemmen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James C. Grotta, MD</last_name>
    <role>Study Director</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Health System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Mercy Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Medical Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intercoastal Medical Group</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Medical Center</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Hospital</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruan Neurology Clinic and Research Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Memorial Medical Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lyden PD, Allgren RL, Ng K, Akins P, Meyer B, Al-Sanani F, Lutsep H, Dobak J, Matsubara BS, Zivin J. Intravascular Cooling in the Treatment of Stroke (ICTuS): early clinical experience. J Stroke Cerebrovasc Dis. 2005 May-Jun;14(3):107-14.</citation>
    <PMID>17904009</PMID>
  </reference>
  <reference>
    <citation>Hemmen TM, Raman R, Guluma KZ, Meyer BC, Gomes JA, Cruz-Flores S, Wijman CA, Rapp KS, Grotta JC, Lyden PD; ICTuS-L Investigators. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. Stroke. 2010 Oct;41(10):2265-70. doi: 10.1161/STROKEAHA.110.592295. Epub 2010 Aug 19.</citation>
    <PMID>20724711</PMID>
  </reference>
  <reference>
    <citation>Lyden P, Ernstrom K, Raman R. Determinants of Pneumonia Risk During Endovascular Hypothermia. Ther Hypothermia Temp Manag. 2013 Mar;3(1):24-27.</citation>
    <PMID>23667781</PMID>
  </reference>
  <reference>
    <citation>Lyden P, Ernstrom K, Cruz-Flores S, Gomes J, Grotta J, Mullin A, Rapp K, Raman R, Wijman C, Hemmen T. Determinants of effective cooling during endovascular hypothermia. Neurocrit Care. 2012 Jun;16(3):413-20. doi: 10.1007/s12028-012-9688-y.</citation>
    <PMID>22466971</PMID>
  </reference>
  <reference>
    <citation>Guluma KZ, Liu L, Hemmen TM, Acharya AB, Rapp KS, Raman R, Lyden PD. Therapeutic hypothermia is associated with a decrease in urine output in acute stroke patients. Resuscitation. 2010 Dec;81(12):1642-7. doi: 10.1016/j.resuscitation.2010.08.003.</citation>
    <PMID>20817376</PMID>
  </reference>
  <reference>
    <citation>Guluma KZ, Hemmen TM, Olsen SE, Rapp KS, Lyden PD. A trial of therapeutic hypothermia via endovascular approach in awake patients with acute ischemic stroke: methodology. Acad Emerg Med. 2006 Aug;13(8):820-7. Epub 2006 Jun 9.</citation>
    <PMID>16766740</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <results_first_submitted>September 29, 2016</results_first_submitted>
  <results_first_submitted_qc>February 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2017</results_first_posted>
  <last_update_submitted>February 18, 2017</last_update_submitted>
  <last_update_submitted_qc>February 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Patrick Lyden</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypothermia</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Cerebral Infarction</keyword>
  <keyword>Hematologic Agents</keyword>
  <keyword>Stroke</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Tissue Plasminogen Activator</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Fibrinolytic Agents</keyword>
  <keyword>Cardiovascular Agents</keyword>
  <keyword>Body Temperature Changes</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Signs and Symptoms</keyword>
  <keyword>Fibrin Modulating Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Brain Ischemia</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Brain Infarction</keyword>
  <keyword>Plasminogen</keyword>
  <keyword>cooling</keyword>
  <keyword>tPA</keyword>
  <keyword>thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group1: IV t-PA and Normothermia</title>
          <description>IV tpa and normothermia
Group1: IV t-PA and normothermia: Group 1 will t-PA as standard of care and normothermia</description>
        </group>
        <group group_id="P2">
          <title>Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment</title>
          <description>IV tpa and hypothermia and anti-shivering treatment
hypothermia: Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine, and surface warming.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients enrolled and randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Group1: IV t-PA and Normothermia</title>
          <description>IV tpa and normothermia
Group1: IV t-PA and normothermia: Group 1 will t-PA as standard of care and normothermia</description>
        </group>
        <group group_id="B2">
          <title>Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment</title>
          <description>IV tpa and hypothermia and anti-shivering treatment
hypothermia: Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine, and surface warming</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="11.1"/>
                    <measurement group_id="B2" value="65.5" spread="10.3"/>
                    <measurement group_id="B3" value="66.4" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline NIHSS</title>
          <description>The NIHSS measures neurological deficit. Scores range from 0 (best) to 42 (worst). Between 0 and 42 higher scores reflect progressively worse neurological deficit.</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" spread="4.9"/>
                    <measurement group_id="B2" value="14.1" spread="4.8"/>
                    <measurement group_id="B3" value="14.3" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline temperature</title>
          <units>degrees (C)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.4" spread="0.50"/>
                    <measurement group_id="B2" value="36.6" spread="0.46"/>
                    <measurement group_id="B3" value="36.5" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome is the Proportion of Patients Achieving a Favorable Outcome Defined as Modified Rankin Scale Score of 0 or 1, Assessed 90 Days After Treatment.</title>
        <description>Modified Rankin describes disability: 0 is free of any disability or symptoms, 6 is death, and higher grades between 0 and 6 reflect progressively greater disability</description>
        <time_frame>90 days</time_frame>
        <population>Intention to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group1: IV t-PA and Normothermia</title>
            <description>IV tpa and normothermia
Group1: IV t-PA and normothermia: Group 1 will t-PA as standard of care and normothermia</description>
          </group>
          <group group_id="O2">
            <title>Group 2 : IV t-PA and Hypothermia</title>
            <description>IV tpa and hypothermia
hypothermia: Hypothermia is induced using the Celsius Control™ System</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome is the Proportion of Patients Achieving a Favorable Outcome Defined as Modified Rankin Scale Score of 0 or 1, Assessed 90 Days After Treatment.</title>
          <description>Modified Rankin describes disability: 0 is free of any disability or symptoms, 6 is death, and higher grades between 0 and 6 reflect progressively greater disability</description>
          <population>Intention to Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Any Intracranial Hemorrhage (ICH) Within 48 Hours of Stroke Onset</title>
        <description>Incidence (number) of any intracranial hemorrhage (ICH) (whether or not symptomatic) within 48 hours of stroke onset will be presented by treatment group and overall.</description>
        <time_frame>48 hours</time_frame>
        <population>Intention to treat patients with imaging obtained 36 to 48 hours after treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Group1: IV t-PA and Normothermia</title>
            <description>IV tpa and normothermia
Group1: IV t-PA and normothermia: Group 1 will t-PA as standard of care and normothermia</description>
          </group>
          <group group_id="O2">
            <title>Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment</title>
            <description>IV tpa and hypothermia and anti-shivering treatment
hypothermia: Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine, and surface warming</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Any Intracranial Hemorrhage (ICH) Within 48 Hours of Stroke Onset</title>
          <description>Incidence (number) of any intracranial hemorrhage (ICH) (whether or not symptomatic) within 48 hours of stroke onset will be presented by treatment group and overall.</description>
          <population>Intention to treat patients with imaging obtained 36 to 48 hours after treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Any Symptomatic Intracranial Hemorrhage (sICH) Within 48 Hours of Stroke Onset</title>
        <description>Incidence (number) of Symptomatic ICH (sICH) within 48 hours of stroke onset will be presented by treatment group and overall. Patients with neuroworsening (4 or more point increase in NIHSS , or a decline in the NIHSS consciousness item 1A score of more than 1 point, or a motor deterioration lasting more than 8 hours, all not due to iatrogenic cause) and hemorrhage seen on brain images in whom the investigator attributes the clinical change to the hemorrhage.</description>
        <time_frame>48 hours</time_frame>
        <population>ITT patients in whom a brain image was obtained 36 yo 48 hours after treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Group1: IV t-PA and Normothermia</title>
            <description>IV tpa and normothermia
Group1: IV t-PA and normothermia: Group 1 will t-PA as standard of care and normothermia</description>
          </group>
          <group group_id="O2">
            <title>Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment</title>
            <description>IV tpa and hypothermia and anti-shivering treatment
hypothermia: Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine, and surface warming</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Any Symptomatic Intracranial Hemorrhage (sICH) Within 48 Hours of Stroke Onset</title>
          <description>Incidence (number) of Symptomatic ICH (sICH) within 48 hours of stroke onset will be presented by treatment group and overall. Patients with neuroworsening (4 or more point increase in NIHSS , or a decline in the NIHSS consciousness item 1A score of more than 1 point, or a motor deterioration lasting more than 8 hours, all not due to iatrogenic cause) and hemorrhage seen on brain images in whom the investigator attributes the clinical change to the hemorrhage.</description>
          <population>ITT patients in whom a brain image was obtained 36 yo 48 hours after treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Pneumonia</title>
        <description>Number subjects diagnosed with pneumonia according to CDC criteria will be presented by treatment group and overall, regardless of seriousness</description>
        <time_frame>7 days or discharge whichever comes first</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Group1: IV t-PA and Normothermia</title>
            <description>IV tpa and normothermia
Group1: IV t-PA and normothermia: Group 1 will t-PA as standard of care and normothermia</description>
          </group>
          <group group_id="O2">
            <title>Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment</title>
            <description>IV tpa and hypothermia and anti-shivering treatment
hypothermia: Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine, and surface warming</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Pneumonia</title>
          <description>Number subjects diagnosed with pneumonia according to CDC criteria will be presented by treatment group and overall, regardless of seriousness</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>90 Day Mortality</title>
        <description>Mortality prior to the 90-day evaluation.</description>
        <time_frame>90 days</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Group1: IV t-PA and Normothermia</title>
            <description>IV tpa and normothermia
Group1: IV t-PA and normothermia: Group 1 will t-PA as standard of care and normothermia</description>
          </group>
          <group group_id="O2">
            <title>Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment</title>
            <description>IV tpa and hypothermia and anti-shivering treatment
hypothermia: Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine, and surface warming.</description>
          </group>
        </group_list>
        <measure>
          <title>90 Day Mortality</title>
          <description>Mortality prior to the 90-day evaluation.</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Barthel Index Measure of Activities of Daily Living;</title>
        <description>The Barthel index measures independence in activities of daily living from 0 (worst) to 100 (best) in 5 point increments. Higher scores between 0 and 100 reflect progressively greater levels of independence. Scores were dichotomized at 90 so that a score of 95 or 100 was considered a successful treatment.</description>
        <time_frame>90 days</time_frame>
        <population>The intention to treat population with a 90-day Barthel index available was used, therefore the numbers are fewer than in the total population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group1: IV t-PA and Normothermia</title>
            <description>IV tpa and normothermia
Group1: IV t-PA and normothermia: Group 1 will t-PA as standard of care and normothermia</description>
          </group>
          <group group_id="O2">
            <title>Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment</title>
            <description>IV tpa and hypothermia
hypothermia: Hypothermia is induced using the Celsius Control™ System. Shivering treatment includes buspirone, meperidine, and surface warming.</description>
          </group>
        </group_list>
        <measure>
          <title>The Barthel Index Measure of Activities of Daily Living;</title>
          <description>The Barthel index measures independence in activities of daily living from 0 (worst) to 100 (best) in 5 point increments. Higher scores between 0 and 100 reflect progressively greater levels of independence. Scores were dichotomized at 90 so that a score of 95 or 100 was considered a successful treatment.</description>
          <population>The intention to treat population with a 90-day Barthel index available was used, therefore the numbers are fewer than in the total population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NIHSS Scores at 90 Days</title>
        <description>The National Institutes of Health Stroke Scale (NIHSS) is used to quantify neurological deficit. The scale ranges from 0 (best) to 42 points (worst). Between scores of 0 to 42, higher values reflect progressively greater deficit.</description>
        <time_frame>90 days</time_frame>
        <population>Intention to treat patients with an available 90-day NIHSS values therefore the total numbers available are fewer than the total ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group1: IV t-PA and Normothermia</title>
            <description>IV tpa and normothermia
Group1: IV t-PA and normothermia: Group 1 will t-PA as standard of care and normothermia</description>
          </group>
          <group group_id="O2">
            <title>Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment</title>
            <description>IV tpa and hypothermia and anti-shivering treatment
hypothermia: Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine, and surface warming</description>
          </group>
        </group_list>
        <measure>
          <title>NIHSS Scores at 90 Days</title>
          <description>The National Institutes of Health Stroke Scale (NIHSS) is used to quantify neurological deficit. The scale ranges from 0 (best) to 42 points (worst). Between scores of 0 to 42, higher values reflect progressively greater deficit.</description>
          <population>Intention to treat patients with an available 90-day NIHSS values therefore the total numbers available are fewer than the total ITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="6.6"/>
                    <measurement group_id="O2" value="4.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for 7 days or discharge whichever came first. Serious adverse events were collected for 90 days.</time_frame>
      <desc>Adverse events and Other (not including serious) events are summarized by system organ class, rather than Adverse Event Terms, due to the small number of subjects and infrequency of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group1: IV t-PA and Normothermia</title>
          <description>IV tpa and normothermia
Group1: IV t-PA and normothermia: Group 1 will t-PA as standard of care and normothermia</description>
        </group>
        <group group_id="E2">
          <title>Group 2 : IV t-PA and Hypothermia and Anti-shivering Treatment</title>
          <description>IV tpa and hypothermia and anti-shivering treatment
hypothermia: Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <description>arrest, CHF, CAD, cardiomyopathy</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <description>bacteremia, sepsis, shock</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>injury</sub_title>
                <description>contusion, muscle injury, pelvic fracture</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism</sub_title>
                <description>dehydration, metabolic acidosis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muskuloskeletal</sub_title>
                <description>ankle fracture</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm</sub_title>
                <description>metastases to meninges</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System Disorders</sub_title>
                <description>agitation, herniation, oedema, carotid artery stenosis, cerebral hemorrhage, confusional state, ICH, sedation, stroke in evolution</description>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="57"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>psychiatric disorders</sub_title>
                <description>delerium</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal</sub_title>
                <description>renal failure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <description>ARDs, respiratory failure, pneumonia, PE, resp distress, resp depression, resp failure</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>vascular</sub_title>
                <description>Arterial rupture, deep vein thrombosis, Hemorrhage, or hypotension</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic</sub_title>
                <description>Total AEs</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="57"/>
                <counts group_id="E2" events="33" subjects_affected="19" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="57"/>
                <counts group_id="E2" events="50" subjects_affected="36" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="57"/>
                <counts group_id="E2" events="38" subjects_affected="34" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>immune</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>investigations</sub_title>
                <counts group_id="E1" events="83" subjects_affected="34" subjects_at_risk="57"/>
                <counts group_id="E2" events="139" subjects_affected="52" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous Systen</sub_title>
                <counts group_id="E1" events="54" subjects_affected="33" subjects_at_risk="57"/>
                <counts group_id="E2" events="46" subjects_affected="37" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="57"/>
                <counts group_id="E2" events="44" subjects_affected="31" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="57"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Patrick Lyden</name_or_title>
      <organization>Cedars-Sinai Medical Center</organization>
      <phone>310-423-5166</phone>
      <email>lydenp@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

